Status:
NOT_YET_RECRUITING
Effect of Acute Endurance Exercise on the Production of FGF21 and Follistatin in Patients With Hepatocellular Carcinoma
Lead Sponsor:
University Hospital, Clermont-Ferrand
Conditions:
Cirrhosis With Hepatocellular Carcinoma
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The main purpose of the study is to characterize the production of hepatokines (FGF21 and Follistatin) in response to a submaximal exercise on an ergocycle, in patients with hepatocellular carcinoma. ...
Eligibility Criteria
Inclusion
- Hepatocellular carcinoma developed on cirrhosis
- Cirrhosis of any etiology, defined by a liver elasticity measurement \>15kPa or a history of cirrhosis decompensation
- Hepatocellular carcinoma with indication for treatment by immunotherapy or chemoembolization
- Child-Pugh scores A and B7
- WHO score ≤ 2
- Affiliation to french national social security system
Exclusion
- Hepatic encephalopathy grade II or higher
- Bone metastasis
- Surgery performed within 30 days prior to inclusion visit
- Liver transplant
- Muscle injury within 3 months of inclusion
- Pregnant or breast-feeding women
- Patients under legal protection (guardianship, curatorship, safeguard of justice)
- Participation in another clinical trial within 10 days of inclusion
Key Trial Info
Start Date :
December 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2029
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT07189624
Start Date
December 1 2025
End Date
April 1 2029
Last Update
December 31 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Estaing Medecine Digestive Et Hepatobiliaire
Clermont-Ferrand, France, 63003
2
CHU de Clermont-Ferrand
Clermont-Ferrand, France